Creative Diagnostics announces the release of a specialized portfolio of Antibiotic Residue Detection ELISA Kits. NEW ...

WuXi Biologics and Sinorda Biomedicine collaborate to accelerate development and manufacturing of innovative bispecific antibody: Shanghai Friday, January 30, 2026, 10:00 Hrs [IST ...

WuXi Biologics and Sinorda Biomedicine have jointly announced a strategic collaboration for the development and manufacturing of SND006.

WuXi Biologics (2269.HK), a leading global Contract Research, Development, and Manufacturing Organization (CRDMO), and Sinorda Biomedicine today jointly ...

Key market opportunities include the surge in biopharmaceutical outsourcing for nucleic acid production, driven by demand for ...

The global biologics CRO market, driven by increased biologics demand, outsourcing, and personalized medicine needs, offers ...

Non-specific Endonuclease Market to reach US$ 726.6 Bn by 2036 at 6.5% CAGR, driven by rising biotechnology research, ...

INCHEON, South Korea, Jan. 28, 2026 /PRNewswire/ -- Samsung Biologics (KRX: 207940.KS), a leading contract development and manufacturing organization (CDMO), announced that it has received the ...

Lonza reported sales of 6.5 billion Swiss francs last year (about $8.5 billion in U.S. dollars) reflecting constant exchange rate (CER) sales growth of 21.7 percent, according to a release issued ...

Lonza Group stock is a top CDMO benefiting from biopharma outsourcing, strong growth, and expanding margins. Learn more about ...

XINTAI, SHANDONG, CHINA, January 19, 2026 /EINPresswire.com/ -- In recent years, the global pharmaceutical packaging ...

GLP-1 therapies are a cornerstone for the management of type 2 diabetes, supporting glycemic control and improving ...